Monoclonal antibody treatment of colorectal cancer.

Abstract

The recent development of adjuvant monoclonal antibody immunotherapy for patients suffering from colorectal cancer has led to a re-evaluation of the role of these molecules in the treatment of solid tumours. In particular, interest has been directed at identifying appropriate candidates for therapy, evaluating treatment schedules and developing new molecules of therapeutic potential. This is a review of published data on patients undergoing antibody therapy. In addition, current theories of the mechanism of action of antitumour monoclonal antibodies are presented, along with potential future therapeutic approaches. Monoclonal antibody-based adjuvant therapy of colorectal cancer appears to be effective; international multicentre trials continue. The development of new molecules, such as chimaeric antibodies, offers the potential of increased tumour targeting with reduced toxicity. Such molecules may be used alone or in combination with agents such as chemotherapy or cytokines.